Abstract: The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component.

Abstract: The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component.

Abstract: The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component.

Abstract: An assay cartridge has a base member (26) that defines at least two wells (30, 32, 34, 36, 38), a pipette (108, 110) positionable in at least one of the wells and a cap member (86) arranged to carry the pipette. The cap member can be releasably fastened to the base member. An extension member (28) defines at least one further well (40, 42, 44) and can be fastened to the base member such that the pipette is then positionable in at least one of the wells of the base and in the further well of the extension member.

Abstract: The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component.

Abstract: The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component.

Abstract: An assay cartridge has a base member (26) that defines at least two wells (30, 32, 34, 36, 38), a pipette (108, 110) positionable in at least one of the wells and a cap member (86) arranged to carry the pipette. The cap member can be releasably fastened to the base member. An extension member (28) defines at least one further well (40, 42, 44) and can be fastened to the base member such that the pipette is then positionable in at least one of the wells of the base and in the further well of the extension member.

Abstract: An assay cartridge has a base member (26) that defines at least two wells (30, 32, 34, 36, 38), a pipette (108, 110) positionable in at least one of the wells and a cap member (86) arranged to carry the pipette. The cap member can be releasably fastened to the base member. An extension member (28) defines at least one further well (40, 42, 44) and can be fastened to the base member such that the pipette is then positionable in at least one of the wells of the base and in the further well of the extension member.

Abstract: An assay cartridge has a base member (26) that defines at least two wells (30, 32, 34, 36, 38), a pipette (108, 110) positionable in at least one of the wells and a cap member (86) arranged to carry the pipette. The cap member can be releasably fastened to the base member. An extension member (28) defines at least one further well (40, 42, 44) and can be fastened to the base member such that the pipette is then positionable in at least one of the wells of the base and in the further well of the extension member.

Abstract: The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component.

Abstract: The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component.

Abstract: An assay method for determining transcobalamin saturation wherein a transcobalamin containing liquid sample is contacted with a porous substrate with immobilized thereon a transcobalamin immobilizing ligand and with a reporter-labelled transcobalamin binding partner and wherein signals from reporter labels which become immobilized on said substrate are detected, characterized in that one of said ligand or said binding partner comprises a first ligand or binding partner capable of specific binding to holo transcobalamin and a second ligand or binding partner capable of binding to apo transcobalamin or to holo and apo transcobalamin.

Abstract: An assay cartridge has a base member (26) that defines at least two wells (30, 32, 34, 36, 38), a pipette (108, 110) positionable in at least one of the wells and a cap member (86) arranged to carry the pipette. The cap member can be releasably fastened to the base member. An extension member (28) defines at least one further well (40, 42, 44) and can be fastened to the base member such that the pipette is then positionable in at least one of the wells of the base and in the further well of the extension member.

Abstract: The invention provides an enzymatic method for measuring the concentration of one or more analytes in the plasma portion of a blood derived sample, containing a first and a second component, where said second component interferes with the measurement of said first component.

Abstract: The present invention provides a specific binding partner for holoTC having a specificity for holoTC over apoTC of at least 40-fold and an assay method for assaying for holoTC in a sample, the method comprising contacting the sample with a specific binding partner for holoTC and detecting the resultant conjugates.

Abstract: The present invention provides a specific binding partner for holoTC having a specificity for holoTC over apoTC of at least 40-fold and an assay method for assaying for holoTC in a sample, the method comprising contacting the sample with a specific binding partner for holoTC and detecting the resultant conjugates.

Abstract: The present invention provides a specific binding partner for holoTC having a specificity for holoTC over apoTC of at least 40-fold and an assay method for assaying for holoTC in a sample, the method comprising contacting the sample with a specific binding partner for holoTC and detecting the resultant conjugates.

Abstract: A molecule which recognises holo-DBP but which does not recognise apo-DBP or has relatively low affinity thereto.

Abstract: The present invention provides a specific binding partner for holoTC having a specificity for holoTC over apoTC of at least 40-fold and an assay method for assaying for holoTC in a sample, the method comprising contacting the sample with a specific binding partner for holoTC and detecting the resultant conjugates.

Abstract: An assay method for determining transcobalamin saturation wherein a transcobalamin containing liquid sample is contacted with a porous substrate with immobilized thereon a transcobalamin immobilizing ligand and with a reporter-labelled transcobalamin binding partner and wherein signals from reporter labels which become immobilized on said substrate are detected, characterised in that one of said ligand or said binding partner comprises a first ligand or binding partner capable of specific binding to holo transcobalamin and a second ligand or binding partner capable of binding to apo transcobalamin or to holo and apo transcobalamin.